Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Obinutuzumab (Gazyva) for Follicular Lymphoma
(Open for Feedback on Recommendation until April 13, 2017)

Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed)
(Final Recommendation Issued as of March 30, 2017)

Vandetanib (Caprelsa) for Medullar Thyroid Cancer
(Final Recommendation Issued as of March 30, 2017)

Ceritinib (Zykadia) for Non-Small Cell Lung Cancer (Resubmission)
(Final Recommendation Issued as of March 21, 2017)

Olaparib (Lynparza) Resubmission for Ovarian Cancer
(Open for Input on Submission as of March 20, 2017)

Irinotecan Liposome (Onivyde) for Metastatic Pancreatic Cancer
(Pending Submission as of March 10, 2017)

Dabrafenib & Trametinib (Tafinlar & Mekinist) in combo for Non-Small Cell Lung Cancer
(Pending Submission as of March 2, 2017)

 

 

Find a Drug Review